-
Mashup Score: 5Nvidia vs. AMD vs. Intel: Comparing AI Chip Sales - 8 month(s) ago
The generative AI boom is powered by processors. How have AI chip sales grown over the last two years among Nvidia vs AMD vs Intel?
Source: www.visualcapitalist.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report - 8 month(s) ago
Background/aims To further validate the Vision Impairment in Low Luminance (VILL) questionnaire, which captures visual functioning and vision-related quality of life (VRQoL) under low luminance, low-contrast conditions relevant to age-related macular degeneration (AMD). Methods The VILL was translated from German into English (UK), Danish, Dutch, French, Italian and Portuguese. Rasch analysis was used to assess psychometric characteristics of 716 participants (65% female, mean age 72±7 years, 82% intermediate AMD) from the baseline visit of the MACUSTAR study. In a subset of participants (n=301), test–retest reliability (intraclass correlation coefficient (ICC) and coefficient of repeatability (CoR)) and construct validity were assessed. Results Four items were removed from the VILL with 37 items due to misfit. The resulting Vision Impairment in Low Luminance with 33 items (VILL-33) has three subscales with no disordered thresholds and no misfitting items. No differential item function
Source: bjo.bmj.comCategories: Latest Headlines, OphthalmologyTweet-
How do you assess vision impairment from patients' standpoint in #AMD? The Vision Impairment in Low Luminance (#VILL) can capture patient-reported outcomes in future trials, according to the #MACUSTAR study: https://t.co/FQsu45jS0j ⭐ 🤩 #retina #ophthalmology #ophthotwitter https://t.co/QiP95Xs1AL
-
-
Mashup Score: 0
New 96-week data from PULSAR show patients treated with aflibercept 8 mg achieved good durability and maintained visual acuity gains from year 1 through year 2 of study.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
Topline 2-year data from PULSAR report durable vision gains and extended dosing with aflibercept 8mg in wet #AMD treatment. Read more: https://t.co/1tSvR7ivH4
-
-
Mashup Score: 0Expanding Retina’s Armamentarium - 9 month(s) ago
By Christine Yue Leonard, Senior Associate Editor W ithin the space of just a few years, several new retinal treatments have been ap proved for wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion, promising increased durability and better drying. These toolbox additions are encouraging for treating resistant and newly diagnosed patients. As with any newly available treatment, uptake is often gradual, and doctors may wonder whether it’s worth it to stock another drug.
Source: www.reviewofophthalmology.comCategories: Latest Headlines, OphthalmologyTweet-
Expanding Retina’s Armamentarium Here’s how specialists are using the latest treatments for wet AMD, DME and RVO. Read the feature from the new August issue: https://t.co/Ivh6dASTL6 #retina #ophthalmology #ophthalmologist #retinaspecialist #AMD #maculardegeneration https://t.co/tKu7VNsrg0
-
-
Mashup Score: 0
New 96-week data from PULSAR show patients treated with aflibercept 8 mg achieved good durability and maintained visual acuity gains from year 1 through year 2 of study.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
Positive topline 2-year data from the PULSAR trial suggest durable vision gains and extended dosing intervals with aflibercept 8 mg treatment in patients with wet #AMD. Read more: https://t.co/AfyIMTKa6z #ophthalmology
-
-
Mashup Score: 4BREAKING NEWS: Iveric Bio receives FDA approval for avacincaptad pegol intravitreal solution for treatment of geographic atrophy - 9 month(s) ago
According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.
Source: www.ophthalmologytimes.comCategories: Latest Headlines, OphthalmologyTweet-
Astellas Pharma Inc. announced the FDA has approved @IvericBio's avacincaptad pegol intravitreal solution (for the treatment of geographic atrophy secondary to age-related macular degeneration. #Ophthalmology #geographicatrophy #AMD https://t.co/C2xRgtz5H7
-
-
Mashup Score: 0
The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
#ICYMI The FDA issued a CRL for the BLA for aflibercept 8mg for the treatment of wet #AMD and #DME, related to an ongoing review of findings from a third-party filler inspection. Read more: https://t.co/pLP8vPKHkV
-
-
Mashup Score: 2Advanced Age-Related Macular Degeneration: How to Use Imaging to Screen and Monitor Patients - 11 month(s) ago
A quarter of people aged over 60 have early or intermediate age-related macular degeneration (AMD). Do you know how to assess these patients and determine follow-up schedules?
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
📍 A quarter of people aged over 60 have early or intermediate age-related macular degeneration. Do you know how to assess these patients and determine follow-up schedules? #AMD ➡️ https://t.co/MOQLsc3mAh https://t.co/GfVv8200A8
-
-
Mashup Score: 6
Undergoing multiple intravitreal injections for age-related macular degeneration may have a positive impact on dry eye disease–related symptoms.
Categories: Latest Headlines, OphthalmologyTweet-
Serial #antiVEGF injections for #AMD can have positive outcomes, says research reviewed by @zeba_almas. https://t.co/nNvLS3JW8A #cornea #AMD
-
-
Mashup Score: 0
Despite ease of use, the Amsler grid may not have adequate sensitivity or specificity to make it a reliable at-home tool for monitoring the progression of AMD.
Categories: Latest Headlines, OphthalmologyTweet-
A recent study suggests that the #amslergrid isn't as black and white as initially thought when it comes to home-monitoring of #AMD. https://t.co/QoTI5fPMyQ #cornea #comprehensiveophthalmology
-
#Nvidia vs. #AMD vs. #Intel: Comparing #AI Chip Sales! https://t.co/HxmQfYVTXJ via @visualcap #GenAI https://t.co/apJxv3pz2i